Deal Activity Overview - The total deal value for 2025 reached approximately $2.4 trillion, a significant increase from about $1.83 trillion in 2024, driven by high-value agreements in corporate M&A and private equity buyouts [1] - Middle-market deal volume was low in 2025, with large M&A transactions inflating overall statistics, marking a decade-high level of megadeals, which were double the number from the previous year [2] Historical Context - 2021 remains the peak year for U.S. deal activity, with 19,666 deals valued at roughly $5.55 trillion, influenced by low interest rates at that time [3] Market Conditions - The sluggishness in dealmaking during the first half of 2025 was attributed to uncertainty from Trump's tariff announcements, which created a challenging environment for executives [4][6] - The consumer sector saw a 17% decline in deal value during the first three quarters of 2025 compared to the same period in 2024, while industrials, energy, and healthcare sectors experienced growth in transaction values [8] Sector-Specific Insights - In the retail space, there were 227 U.S. deals recorded through mid-December 2025, down from 296 in the previous year, but the total valuation exceeded $40 billion, compared to approximately $28.4 billion in 2024 [9] - The automotive industry faced a 19.9% decline in deal volume year-over-year, reflecting broader challenges in the industrial manufacturing sector [17] Regulatory Environment - The Trump administration's policies have influenced deal approvals, with companies like Verizon altering their diversity policies to facilitate regulatory approvals for significant acquisitions [20][21] - The merger of Paramount Skydance was approved after the company agreed to eliminate DEI initiatives, showcasing the regulatory landscape's impact on deal-making [21] Future Outlook - The second half of 2025 saw a resurgence in deal activity, particularly in the banking sector, which experienced an 88% increase in announced deals, with total transaction sizes nearly quadrupling to $39 billion [29] - There is optimism for continued deal-making activity in 2026, especially among regional banks, driven by activist investors and a more favorable regulatory environment [30][31]

Weight loss drug Mounjaro’s manufacturer, Eli Lilly and Co. (NYSE:LLY) has crossed a significant threshold in Benzinga Edge's Stock Rankings, moving into the top decile for quality this week. This improvement in fundamental strength coincides with a bullish note from Bank of America, which argues the market is still underestimating the pharmaceutical giant’s dominance in the obesity sector.Check out LLY’s price here.Entering The Top DecileIn the latest weekly data update, Eli Lilly's quality score advanced ...

Weight loss drug Mounjaro’s manufacturer, Eli Lilly and Co. (NYSE:LLY) has crossed a significant threshold in Benzinga Edge's Stock Rankings, moving into the top decile for quality this week. This improvement in fundamental strength coincides with a bullish note from Bank of America, which argues the market is still underestimating the pharmaceutical giant’s dominance in the obesity sector.Check out LLY’s price here.Entering The Top DecileIn the latest weekly data update, Eli Lilly's quality score advanced ...

责任编辑：郭明煜 Altimmune公司（Altimmune）于周五宣布，在一项针对代谢相关脂肪性肝炎（MASH）患者开展的中期 临床试验中，其在研药物经过 48 周治疗后，显著改善了患者的肝纤维化症状及肝脏健康指标。 该公司股价在盘前交易中上涨 7.3%。 该公司股价在盘前交易中上涨 7.3%。 责任编辑：郭明煜 Altimmune公司（Altimmune）于周五宣布，在一项针对代谢相关脂肪性肝炎（MASH）患者开展的中期 临床试验中，其在研药物经过 48 周治疗后，显著改善了患者的肝纤维化症状及肝脏健康指标。 ...

Aristotle Capital Boston, LLC, an investment advisor, released its “Small Cap Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter, the small-cap equities delivered strong results with the Russell 2000 Index reaching its first all-time high since November 2021. A favorable macroeconomic backdrop led the rally. In the quarter, the fund (Class I-2) delivered a return of 3.16% underperforming the 12.39% total return of the Russell 2000 Index. For mo ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. BioMarin Pharmaceutical has agreed to buy Amicus Therapeutics in a $4.8 billion deal that would hand it two marketed drugs for rare diseases and a third asset in late-stage human testing. The all-cash acquisition, announced Friday, has BioMarin paying $14.50 for each Amicus share, or a 33% premium to the latter’s closing stock price on Thursday. The deal has u ...

Core Viewpoint - Ningbo Meinuohua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the raw material drug Atorvastatin Calcium, which will enhance the company's product line and business scope [1][3]. Group 1: Registration Information - The registration number for Atorvastatin Calcium is Y20240000440, and it is produced by Xuancheng Meinuohua Pharmaceutical Co., Ltd. in Anhui [1]. - The product is available in various packaging specifications: 5kg, 10kg, 15kg, 20kg, and 25kg [1]. - The approval indicates that the product meets the requirements for drug registration under the Drug Administration Law of the People's Republic of China [1]. Group 2: Indications and Pharmacological Action - Atorvastatin Calcium is indicated for the treatment of hypercholesterolemia and mixed hyperlipidemia, as well as for the prevention and treatment of coronary heart disease [2]. - The drug functions as a statin, primarily acting in the liver to reduce cholesterol synthesis, increase low-density lipoprotein receptor synthesis, lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately decrease serum triglyceride levels, and increase high-density lipoprotein levels [2]. Group 3: Impact on the Company - Xuancheng Meinuohua submitted the review application for Atorvastatin Calcium on May 16, 2024, and it passed the review on December 17, 2025, with a cumulative R&D investment of 14.9496 million yuan [3]. - The approval of Atorvastatin Calcium demonstrates compliance with national drug review technical standards, allowing the product to be sold in the domestic market, which will enrich the subsidiary's product line and help expand the company's business scope [3].

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 雌二醇片/雌二醇地屈孕酮片复合包装，参比制剂为原研进口的雌二醇片/雌二醇地屈孕酮片复合包装， 商品名：芬吗通?（Femoston?）。雌二醇片/雌二醇地屈孕酮片复合包装参比制剂由Abbott B.V.开发，两 个规格最早分别于1995年2月和1998年4月在荷兰批准上市；2005年，芬吗通?在中国获批进口。雌二醇 片/雌二醇地屈孕酮片复合包装的适应症为用于治疗自然或术后绝经所致的围绝经期综合症。目前， Abbott B.V.的Femoston?已在荷兰、葡萄牙、德国等多个国家上市销售。 登录新浪财经APP 搜索【信披】查看更多考评等级 本次公司申报的雌二醇片/雌二醇地屈孕酮片复合包装规格与原研已批准上市的规格一致，按化学药品4 类进行申报。 三、对公司的影响及风险提示 雌二醇片/雌二醇地屈孕酮片复合包装被国家药品监督管理局受理，标志着该品种境内生产药品注册工 作进入了审评阶段，公司将积极推进后续相关工作，如顺利通过审批将丰富公司的产品线，有利于提升 公司的市场竞争力。药品注册审批工作流程有一定时间周期，存在不确定 ...

Leadership Changes - BeOne Medicines has promoted Wang Lai to the newly created role of co-president, indicating a leadership expansion as the company advances its late-stage pipeline and globalization efforts [1] - Wang, who has been the global head of R&D since April 2021, will retain his R&D responsibilities while also overseeing business development and managing business alliance relationships starting January [2][4] Financial Performance - BeOne generated global revenue of approximately US$3.8 billion last year, a significant increase from US$1.4 billion in the previous year, driven by flagship products Brukinsa and Tevimbra [6] - Brukinsa achieved global sales of 18.7 billion yuan in 2024, ranking second globally and first in China in its class, contributing to the company's first profitable half-year in early 2024 [6] Product Development - Tevimbra, a PD-1 antibody treatment, has received regulatory approvals across the EU's 27 member states, Iceland, Norway, and 16 other countries in North America, Europe, and Asia-Pacific [7]

2025年12月18日，"肠道健康全民行"社区健康科普活动在江苏南通启动。本次活动由家庭医生在线、中 国药文化研究会国医国药文化传承分会联合主办，老百姓大药房南通普泽连锁有限公司、老百姓大药房 丰沃达医药科技(江苏)有限公司、南京正大天晴制药有限公司、共同支持。活动围绕肠道健康主题，通 过知识普及、现场检测与专业指导相结合的方式，为社区居民提供系统化公益健康服务，助力"健康中 国"在基层落地。 多方携手，共担健康使命 肠道健康是健康体系的重要组成部分。根据相关调查，我国成年人群中肠道健康问题较为普遍，而定期 进行肠道健康检查的比例仍相对较低。数据显示，我国成人慢性便秘患病率约为4%～6%，60岁以上人 群慢性便秘患病率可达22%；据国家卫健委2024年发布的《中国居民肠道健康白皮书》显示，我国约有 62.3%的成年人存在不同程度的肠道健康问题，仅21.5%的受访者表示会定期进行肠道健康检查。提高 公众对肠道健康的认知水平，推动相关疾病的早期预防与干预，已成为落实"健康中国"战略的重要环 节。 活动致辞环节中，支持单位代表们围绕"肠道健康全民行"的社区意义与企业责任展开分享，体现了多方 力量共同投身健康公益的决 ...